Today: 7 February 2026
Subscribe

Shan Ahmed Khan

As a journalist focused on finance and the stock market, he delivers fast, reliable, and easy-to-understand coverage of market news.

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

Viking Therapeutics stock sinks as Novo’s Wegovy pill debut resets obesity-drug pricing

New York, January 5, 2026, 14:21 EST — Regular session Shares of Viking Therapeutics (VKTX) slid 9.9% to $31.93 in afternoon trading on Monday as obesity-drug stocks reacted to Novo Nordisk’s U.S. launch of a Wegovy weight-loss pill. Novo’s U.S.-listed shares rose 5.1%, while Eli Lilly fell 3.9% and the SPDR S&P Biotech ETF dropped 2.2%. The move highlights how sensitive obesity-drug developers remain to pricing signals from the market leaders. Viking has no approved products, so changes in expected pricing can hit the stock as hard as trial data. Direct-to-consumer discounts are also changing how investors think about margins
5 January 2026
······
Wave Life Sciences stock drops 8% as JPM Healthcare Conference looms; obesity data in focus

Wave Life Sciences stock drops 8% as JPM Healthcare Conference looms; obesity data in focus

New York, January 5, 2026, 1:09 PM ET — Regular session Wave Life Sciences Ltd shares fell $1.34, or 8.4%, to $14.61 in afternoon trade on Monday, extending a sharp pullback in the clinical-stage biotech even as the company flagged an investor-conference appearance next week. The move matters because the J.P. Morgan Healthcare Conference often sets the tone for biotech investing early in the year, and Wave’s stock has become closely tethered to expectations for updates on its obesity program and financing needs. Biotech lagged more broadly, with the SPDR S&P Biotech ETF down about 2.1% and the iShares Nasdaq
5 January 2026
····
Gulfport Energy stock (GPOR) slides nearly 9% on Wolfe downgrade as gas prices fall

Gulfport Energy stock (GPOR) slides nearly 9% on Wolfe downgrade as gas prices fall

New York, Jan 5, 2026, 13:05 EST — Regular session Gulfport Energy Corporation shares fell 8.7% on Monday after Wolfe Research analyst Carlos Escalante cut the U.S. gas producer to Peer Perform from Outperform. The stock traded at $188.26 after swinging between $209.00 and $187.93. GuruFocus The call matters now because investors have been repricing gas-linked cash flows as the fuel’s latest pullback deepens. U.S. natural gas fell about 3.5% to $3.49 per million British thermal units, according to TradingEconomics data. Trading Economics Escalante wrote that Wolfe lowered its long-term U.S. gas price forecast by 25 cents to $4.00 per
5 January 2026
·····
SiTime stock slumps 9% after topping Wall Street targets, bucking chip rally

SiTime stock slumps 9% after topping Wall Street targets, bucking chip rally

New York, Jan 5, 2026, 13:54 EST — Regular session SiTime Corp shares slid about 9% on Monday afternoon, reversing an earlier rise and wiping out a chunk of the timing-chip maker’s start-of-year gains. The Nasdaq-listed stock was down $33.46 at $336.50, after trading as high as $382 and as low as $333.33. The move matters because SiTime has become a high-beta way to play the semiconductor cycle, and investors are reassessing richly valued niche chip names as 2026 gets underway. A sharp intraday turn like Monday’s often signals fast money leaving crowded positions, even when the broader sector is
5 January 2026
·····
Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

Structure Therapeutics stock slides nearly 8% as Novo’s Wegovy pill debut jolts oral obesity-drug bets

NEW YORK, Jan 5, 2026, 13:54 EST — Regular session Structure Therapeutics shares fell 7.7% to $62.86 in afternoon trade on Monday, paring an earlier rally and marking another volatile session for the obesity-drug developer. The stock has ranged from $72.02 to $62.50 so far in the regular session. The move came as Novo Nordisk began U.S. sales of a once-daily pill version of Wegovy, bringing a branded oral option into pharmacies at $149 a month for starter doses for self-paying patients, Reuters reported. Novo’s website shows higher-dose pricing at $299 a month, with the 4 mg dose set to
5 January 2026
······
Astera Labs stock drops 8% after insider sale plan disclosed — what traders watch next

Astera Labs stock drops 8% after insider sale plan disclosed — what traders watch next

New York, Jan 5, 2026, 13:45 EST — Regular session Astera Labs shares fell 8.4% to $164.50 on Monday, after swinging from a session high near $185 to a low around $162.5. More than 5 million shares had traded by early afternoon. The move matters because Astera has become a high-volatility proxy for investor appetite for AI infrastructure spending, where sentiment can turn quickly on positioning and supply. A sharp reversal early in the year can amplify stop-loss selling and make intraday liquidity more fragile. Insider-selling signals draw extra attention in fast-rising semiconductor names, even when the amounts are small
5 January 2026
·····
Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

Arrowhead Pharmaceuticals stock slides despite Health Canada approval of Redemplo — what investors watch next

New York, Jan 5, 2026, 13:31 EST — Regular session Arrowhead Pharmaceuticals shares were down about 6.9% on Monday after the company said Health Canada approved Redemplo, its triglyceride-lowering drug for familial chylomicronemia syndrome. The stock fell $4.68 to $63.11 after swinging between $60.75 and $70.87. MarketScreener The clearance gives Arrowhead another regulated market for its first commercial product, as investors shift attention from the science to execution. It also keeps the spotlight on how quickly the company can convert approvals into reimbursed prescriptions. The selloff underscored how hard it can be for single-stock catalysts to cut through sector tape.
5 January 2026
·····
AAOI stock slides nearly 11% after $41 pop; what Applied Optoelectronics investors watch next

AAOI stock slides nearly 11% after $41 pop; what Applied Optoelectronics investors watch next

New York, Jan 5, 2026, 13:30 EST — Regular session Applied Optoelectronics, Inc. (AAOI) shares fell nearly 11% on Monday, erasing an early jump that briefly lifted the stock above $41. The retreat came even as broader U.S. equities and chip-related names traded higher, underlining how quickly positioning can flip in the optical components maker. Applied Optoelectronics sells optical transceivers — plug-in hardware that converts electrical signals into light to move data through fiber. Why it matters now: the stock has become a high-beta proxy for capital spending on AI-linked data centers, where demand is shifting toward faster links. Investors
5 January 2026
····
Lumentum stock drops 8% in sharp reversal as optics peers slide; Feb. 5 earnings loom

Lumentum stock drops 8% in sharp reversal as optics peers slide; Feb. 5 earnings loom

New York, Jan 5, 2026, 13:11 (ET) — Regular session Shares of Lumentum Holdings Inc (LITE.O) fell 8.1% to $354.87 on Monday, after trading between $345 and $394.48 in a volatile session. About 4.2 million shares had changed hands by early afternoon. The slide puts one of the market’s most closely watched optics names back under pressure after a late-2025 run that pushed the stock toward record territory. The move matters now because expectations for AI-linked data-center optics have risen fast, and that leaves less tolerance for a softer outlook when companies next report. Optical components are laser-based parts that
5 January 2026
····
Ciena stock sinks as optics rally cools; traders eye short-interest uptick and next catalysts

Ciena stock sinks as optics rally cools; traders eye short-interest uptick and next catalysts

New York, Jan 5, 2026, 13:20 EST — Regular session Ciena Corp shares were down about 7.8% at $226.75 in midday New York trading on Monday, after touching $253.30 earlier in the session and then sliding to a low of $223.61. The move stood out against a firmer tape: the S&P 500 ETF and Nasdaq 100 ETF were both higher, while optical components maker Lumentum dropped about 7.7%, pointing to a broader unwind in parts of the AI-networking trade. Why it matters now is valuation. In a note published Monday, Zacks Equity Research highlighted Ciena’s premium multiple — a forward
5 January 2026
······
Abivax stock slides 9% in U.S. trade as biotech weakens; ECCO 2026 looms

Abivax stock slides 9% in U.S. trade as biotech weakens; ECCO 2026 looms

New York, January 5, 2026, 13:03 EST — Regular session Abivax (ABVX) shares fell about 9.1% to $121.64 in midday U.S. trading on Monday, after touching $133.73 earlier in the session. The stock hit a low of $121.08, while its Paris-listed shares ended down 9.7%. Investing The pullback matters because Abivax has turned into a high-beta biotech name, where sentiment swings can be abrupt and outsized. Investors have been weighing a rich valuation built on late-stage trial hopes and deal chatter, and Monday’s drop tested how much of that optimism is still in the price. The move came as biotech
5 January 2026
···
Claire’s and TOFS teeter on administration as UK high street faces fresh jobs shock

Claire’s and TOFS teeter on administration as UK high street faces fresh jobs shock

London, January 5, 2026, 17:53 GMT Claire’s and The Original Factory Shop (TOFS) are close to filing notices of intention to appoint administrators, a step that would shield the retailers from creditor action while they pursue a rescue, Sky News reported on Monday. ( source) The chains employ about 2,500 people and trade from just over 300 stores, the report said. The filings would come just after the Christmas trading period, when UK retailers typically make a large share of annual profit. The timing matters because it lands at the start of the year, as large retailers prepare to disclose
5 January 2026
·
1 … 414 415 416 417 418 … 885

Stock Market Today

Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

7 February 2026
Vodafone shares rose 1.47% to 110.60p Friday, recovering part of Thursday’s 4.68% drop after a Q3 update. Group revenue climbed 6.5% to €10.5 billion, but Germany’s 0.7% service revenue growth missed some forecasts. Vodafone launched a new €500 million buyback tranche, bringing total buybacks since May to €3.5 billion. Investors remain focused on Germany’s pace and cash flow execution.
NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

7 February 2026
NatWest shares closed up 1.45% at 659.4 pence Friday, buoyed by a buyback of 797,428 shares and a new digital mortgage deal with Rightmove. The Bank of England held rates at 3.75% but signaled possible cuts, with markets pricing in two reductions for 2026. NatWest plans to expand its Accelerator community to 50,000 members by 2026. Annual results are due Feb. 13.
Unilever share price holds at 5,250p as results week looms — what investors watch next

Unilever share price holds at 5,250p as results week looms — what investors watch next

7 February 2026
Unilever shares closed flat at 5,250p in London Friday, underperforming the FTSE 100’s 0.6% gain. The company issued 4.2 million new shares for employee plans, bringing total shares to over 2.18 billion. Investors await Q4 and full-year results on Feb. 12, with analyst consensus pointing to 3.9% Q4 sales growth. Unilever’s U.S. ADR rose 0.8% to $72.12.
BP share price near 52-week high ahead of Feb 10 earnings as buyback runs on

BP share price near 52-week high ahead of Feb 10 earnings as buyback runs on

7 February 2026
BP shares closed up 1.9% at 478 pence Friday, just below a 52-week high, as the company continued buybacks ahead of next week’s results. BP repurchased 2.789 million shares on February 6. Oil prices firmed on geopolitical risk, with Brent at $68.05 a barrel, but sector outlook remains uncertain. Investors await BP’s earnings and dividend decision due Tuesday.
Go toTop